公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2023 | Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma | Lee, Po-Hsin; CHUN-JU CHIANG ; Tseng, Jeng-Sen; Zheng, Zhe-Rong; Chen, Kun-Chieh; Chu, Cheng-Hsiang; Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; WEN-CHUNG LEE ; Yang, Tsung-Ying; Liu, Tsang-Wu; Hsia, Jiun-Yi; Chang, Gee-Chen | Frontiers in Oncology | 1 | 1 | |
2020 | ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients | Chang, Gee-Chen; Yang, Tsung-Ying; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; Huang, Yen-Hsiang; KANG-YI SU ; SUNG-LIANG YU ; Tseng, Jeng-Sen | Scientific reports | 26 | 20 | |
2018 | The association of acquired T790M mutation with clinical characteristics after resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Chen, Kun-Chieh; Hsu, Chia-Hung; KANG-YI SU ; Chen, Jeremy J W; HUEI-WEN CHEN ; SUNG-LIANG YU ; Yang, Tsung-Ying; Chang, Gee-Chen | Cancer Research and Treatment | 47 | 45 | |
2022 | Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant) | Wu, Jia-Jun; Lee, Po-Hsin; Zheng, Zhe-Rong; Huang, Yen-Hsiang; Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Yang, Tsung-Ying; SUNG-LIANG YU ; Chen, Kun-Chieh; Chang, Gee-Chen | Medicine | 0 | 0 | |
2022 | The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Chin, Chun-Shih; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Cancer research and treatment | 9 | 6 | |
2022 | Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Targeted oncology | 0 | 0 | |
2022 | The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan | Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Chang, Gee-Chen | Targeted oncology | 7 | 7 | |
2015 | Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma | Tseng, Jeng-Sen; Yang, Tsung-Ying; Tsai, Chi-Ren; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; Tsai, Meen-Hsin; SUNG-LIANG YU ; KANG-YI SU ; Chen, Jeremy J. W.; MONG-HSUN TSAI | Journal of Thoracic Oncology | 63 | 61 | |
2017 | EGFR mutation, smoking, and gender in advanced lung adenocarcinoma | Tseng, Chien-Hua; CHUN-JU CHIANG ; Tseng, Jeng-Sen; Yang, Tsung-Ying; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; Wang, Chih-Liang; Chen, Chih-Yi; Yen, Sang-Hue; Tsai, Chun-Ming; Huang, Ming-Shyan; CHAO-CHI HO ; CHONG-JEN YU ; Tsai, Ying-Huang; JIN-SHING CHEN ; Chou, Teh-Ying; Tsai, Ming-Hsun; Chen, Hsuan-Yu; KANG-YI SU ; Chen, Jeremy J. W.; HUEI-WEN CHEN ; SUNG-LIANG YU ; Liu, Tsang-Wu; MONG-HSUN TSAI | Oncotarget | 54 | 41 | |
2021 | Genome-wide epigenetic landscape of lung adenocarcinoma links HOXB9 DNA methylation to intrinsic EGFR-TKI resistance and heterogeneous responses | SU, SHENG-FANG ; Liu, Chia-Hsin; Cheng, Chiou-Ling; CHAO-CHI HO ; Yang, Tsung-Ying; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; HUEI-WEN CHEN ; Chang, Gee-Chen; SUNG-LIANG YU ; Li, Ker-Chau | JCO Precision Oncology | 9 | 6 | |
2021 | The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M | Huang, Yen-Hsiang; Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Yang, Tsung-Ying; Chang, Gee-Chen | Scientific reports | 9 | 9 | |
2014 | Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma | Tseng, Jeng-Sen; Wang, Chih-Liang; Huang, Ming-Shyan; CHUNG-YU CHEN ; Chang, Cheng-Yu; Yang, Tsung-Ying; Tsai, Chi-Ren; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; Tsai, Meen-Hsin; SUNG-LIANG YU ; KANG-YI SU ; Wu, Chih-Wei; Yang, Cheng-Ta; Chen, Yuh-Min; MONG-HSUN TSAI | PLoS ONE | 12 | 12 | |
2022 | Influence of the Timing of Leptomeningeal Metastasis on the Outcome of EGFR-Mutant Lung Adenocarcinoma Patients and Predictors of Detectable EGFR Mutations in Cerebrospinal Fluid | Liao, Pei-Ya; Ou, Wei-Fan; KANG-YI SU ; Sun, Ming-Hsi; Huang, Chih-Mei; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; SUNG-LIANG YU ; Huang, Yen-Hsiang; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chang, Gee-Chen | Cancers | 0 | 0 | |
2023 | Low-Dose Computed Tomography Screening in Relatives With a Family History of Lung Cancer | Wang, Chi-Liang; Hsu, Kuo-Hsuan; Chang, Ya-Hsuan; CHAO-CHI HO ; CHUN-JU CHIANG ; Chen, Kun-Chieh; Cheung, Yun-Chung; Huang, Pei-Ching; Chen, Yu-Ruei; Chen, Chih-Yi ; Hsu, Chung-Ping; Hsia, Jiun-Yi; Chen, Hsuan-Yu; Yang, Shi-Yi; Li, Yao-Jen; Yang, Tsung-Ying; Tseng, Jeng-Sen; Chuang, Cheng-Yen; Hsiung, Chao A; Chen, Yuh-Min; Huang, Ming-Shyan; CHONG-JEN YU ; KUAN-YU CHEN ; Su, Wu-Chou; Chen, Jeremy J W; SUNG-LIANG YU ; Chen, Chien-Jen; PAN-CHYR YANG ; Tsai, Ying-Huang; Chang, Gee-Chen | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2 | 0 | |
2022 | PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients | Hsu, Kuo-Hsuan; Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Huang, Yen-Hsiang; Chang, Gee-Chen | Scientific reports | 11 | 9 | |
2024 | Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib | Wu, Jia-Jun; Tseng, Jeng-Sen; Zheng, Zhe-Rong; Chu, Cheng-Hsiang; Chen, Kun-Chieh; MONG-WEI LIN ; Huang, Yen-Hsiang; Hsu, Kuo-Hsuan; Yang, Tsung-Ying; SUNG-LIANG YU ; JIN-SHING CHEN ; CHAO-CHI HO ; Chang, Gee-Chen | Therapeutic advances in medical oncology | 0 | | |
2021 | Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients | Hsu, Kuo-Hsuan; Huang, Jing-Wen; Tseng, Jeng-Sen; Chen, Kuan-Wen; Weng, Yih-Chyang; SUNG-LIANG YU ; Yang, Tsung-Ying; Huang, Yen-Hsiang; Chen, Jeremy J W; Chen, Kun-Chieh; Chang, Gee-Chen | OncoTargets and therapy | 6 | 6 | |
2021 | Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment | Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Zheng, Zhe-Rong; Yang, Tsung-Ying; Chen, Kun-Chieh; Huang, Yen-Hsiang; KANG-YI SU ; SUNG-LIANG YU ; Chang, Gee-Chen | Oncology | 9 | 9 | |
2014 | Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma | Tseng, Jeng-Sen; Yang, Tsung-Ying; Chen, Kun-Chieh; Hsu, Kuo-Hsuan; CHONG-JEN YU ; WEI-YU LIAO ; Tsai, Chi-Ren; Tsai, Meen-Hsin; SUNG-LIANG YU ; KANG-YI SU ; Chen, Jeremy Jw; Chen, Hsuan-Yu; MONG-HSUN TSAI | OncoTargets and Therapy | 15 | 14 | |
2021 | Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M | Huang, Yen-Hsiang; Tseng, Jeng-Sen; Hsu, Kuo-Hsuan; Chen, Kun-Chieh; KANG-YI SU ; SUNG-LIANG YU ; Chen, Jeremy J W; Yang, Tsung-Ying; Chang, Gee-Chen | Scientific reports | 0 | 0 | |